Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

作者：Jain Preetesh; Kantarjian Hagop; Sasaki Koji; Jabbour Elias; Dasarathula Jyothsna; Gonzalez Graciela Nogueras; Verstovsek Srdan; Borthakur Gautam; Wierda William; Kadia Tapan; Del****la Sara; Pierce Sherry; Ravandi Farhad; O'Brien Susan; Cortes Jorge^*

来源：British Journal of Haematology, 2016, 173(1): 114-126.

DOI：10.1111/bjh.13936

• ELN
• European LeukaemiaNet
• chronic myeloid leukaemia
• tyrosine kinase inhibitor (TKI)
• response in CML

This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML-CP). Four hundred and eighty-seven patients treated with imatinib (400mg; IM 400, n=70; 800mg; IM800, n=201), dasatinib (n=107) or nilotinib (n=109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3months, 78%, 17% and 6% at 6months, and 75%, 13% and 13% at 12months, respectively. Rates of optimal response at 3months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6months; and 47%, 77%, 76% and 87% at 12months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all-time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs.

• 出版日期2016-4